白细胞介素-23抑制剂瑞莎珠单抗有效治疗与IgA肾病相关的克罗恩病。
Crohn's Disease Associated With IgA Nephropathy Effectively Treated With the Interleukin-23 Inhibitor Risankizumab.
作者信息
Larson Charlotte, Munir Naim, Rao Panduranga, Farkash Evan, Kathuria Priya, Romain Dustin, Berinstein Jeffery
机构信息
Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Family Medicine, Des Moines, IA.
出版信息
ACG Case Rep J. 2024 Jul 17;11(7):e01437. doi: 10.14309/crj.0000000000001437. eCollection 2024 Jul.
Abstract
Extraintestinal manifestations (EIMs) are common in inflammatory bowel disease (IBD). Renal EIMs, including immunoglobulin A nephropathy (IgAN), are relatively rare. EIMs are important to consider when developing a treatment plan for IBD. Studies differ on whether IBD disease activity correlates with IgAN disease activity. Published guidance on effective therapies for IBD-associated IgAN is limited. This case report suggests that risankizumab, an effective therapy for Crohn's disease, may also be effective in treating Crohn's disease-associated IgAN.
摘要
肠外表现（EIMs）在炎症性肠病（IBD）中很常见。肾脏的肠外表现，包括免疫球蛋白A肾病（IgAN），相对较少见。在制定IBD治疗方案时，考虑肠外表现很重要。关于IBD疾病活动度与IgAN疾病活动度是否相关的研究结果存在差异。关于IBD相关IgAN有效治疗方法的已发表指南有限。本病例报告表明，瑞莎珠单抗作为克罗恩病的一种有效治疗药物，可能对治疗克罗恩病相关IgAN也有效。
相似文献
1
Crohn's Disease Associated With IgA Nephropathy Effectively Treated With the Interleukin-23 Inhibitor Risankizumab.
ACG Case Rep J. 2024 Jul 17;11(7):e01437. doi: 10.14309/crj.0000000000001437. eCollection 2024 Jul.
2
Factors Associated With Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD.
Inflamm Bowel Dis. 2024 Nov 4;30(11):2027-2036. doi: 10.1093/ibd/izad280.
3
Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.
J Clin Med. 2021 Dec 20;10(24):5984. doi: 10.3390/jcm10245984.
4
Prevalence of Classical Extraintestinal Manifestations among Inflammatory Bowel Disease Patients in Saudi Arabia: A Single Tertiary Center Experience.
Saudi J Med Med Sci. 2024 Apr-Jun;12(2):169-174. doi: 10.4103/sjmms.sjmms_139_23. Epub 2024 Apr 5.
5
IgA nephropathy associated with Crohn's disease.
World J Methodol. 2023 Jun 20;13(3):67-78. doi: 10.5662/wjm.v13.i3.67.
6
Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review.
Nephrol Dial Transplant. 2022 Feb 25;37(3):531-539. doi: 10.1093/ndt/gfaa378.
7
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy.
Intest Res. 2021 Oct;19(4):430-437. doi: 10.5217/ir.2020.00067. Epub 2020 Nov 9.
8
Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease.
Curr Treat Options Gastroenterol. 2007 Jun;10(3):178-84. doi: 10.1007/s11938-007-0011-5.
9
Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
Front Immunol. 2023 Oct 26;14:1234535. doi: 10.3389/fimmu.2023.1234535. eCollection 2023.
10
Ocular extraintestinal manifestations and treatments in patients with inflammatory bowel disease.
Front Ophthalmol (Lausanne). 2024 Jan 4;3:1257068. doi: 10.3389/fopht.2023.1257068. eCollection 2023.
引用本文的文献
1
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.
Aliment Pharmacol Ther. 2025 Aug;62(4):400-418. doi: 10.1111/apt.70262. Epub 2025 Jul 2.
2
A case of IgA nephropathy associated with Crohn's disease treated with enteric-coated budesonide.
CEN Case Rep. 2025 May 30. doi: 10.1007/s13730-025-01001-5.
3
Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials.
Therap Adv Gastroenterol. 2025 May 19;18:17562848251338743. doi: 10.1177/17562848251338743. eCollection 2025.
4
IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn's Disease: Study of IgA1 and IgA2 Expression in Glomeruli.
In Vivo. 2025 May-Jun;39(3):1731-1738. doi: 10.21873/invivo.13975.
本文引用的文献
1
IgA nephropathy associated with Crohn's disease.
World J Methodol. 2023 Jun 20;13(3):67-78. doi: 10.5662/wjm.v13.i3.67.
2
Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports.
J Clin Med. 2023 Apr 6;12(7):2726. doi: 10.3390/jcm12072726.
3
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6.
4
Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis.
Dermatol Pract Concept. 2021 Oct 1;11(4):e2021100. doi: 10.5826/dpc.1104a100. eCollection 2021 Oct.
5
IgA Nephropathy in a Patient Treated with Adalimumab.
Case Rep Nephrol Dial. 2021 Jul 28;11(2):233-240. doi: 10.1159/000515585. eCollection 2021 May-Aug.
6
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
Gastroenterology. 2021 Oct;161(4):1118-1132. doi: 10.1053/j.gastro.2021.07.042. Epub 2021 Aug 3.
7
Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review.
Nephrol Dial Transplant. 2022 Feb 25;37(3):531-539. doi: 10.1093/ndt/gfaa378.
8
Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
J Crohns Colitis. 2021 Jul 5;15(7):1236-1243. doi: 10.1093/ecco-jcc/jjaa260.
9
Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study.
J Am Soc Nephrol. 2021 Feb;32(2):411-423. doi: 10.1681/ASN.2020060848. Epub 2020 Nov 11.
10
IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis.
BMC Nephrol. 2020 Aug 26;21(1):366. doi: 10.1186/s12882-020-02015-0.
Zotero 插件